TG Therapeutics stock is surging to new heights today. Why are TGTX shares rallying?
New At-Home Injection Method Shows PromiseThe biotech company announced data from its Phase 1 trial evaluating a high-concentration subcutaneous formulation of the treatment compared to its approved intravenous version. The trial demonstrated a mean bioavailability of greater than 60% relative to IV administration. Additionally, the treatment resulted in B-cell depletion consistent with the IV version, with no new safety signals observed. Local injection-site reactions occurred in less than 5% of patients.Management stated that the pharmacokinetic modeling supports a quarterly subcutaneous dosing regimen. This regimen is currently being evaluated in a fully enrolled Phase 3 trial. Topline data from the Phase 3 study is expected in late 2026 or early 2027, with a potential regulatory approval goal targeted for 2028. If approved, the self-administered formulation could expand the addressable market for the franchise.TGTX Technical Levels To WatchFrom a longer-term trend view, TGTX is still in a constructive uptrend: it's trading 1.7% above the 20-day SMA ($39.95) and 24.7% above the 200-day SMA ($32.59), with a bullish 20-day-over-50-day setup and a golden cross (50-day above 200-day) that formed in April. The stock is also pressing toward the top of its 52-week range ($25.28 low to $44.65 high), which can attract momentum buyers but also brings overhead supply into view.For momentum, MACD is the cleaner lens right now: it's below its signal line with a negative histogram, which suggests upside pressure is cooling versus the prior upswing unless buyers can re-accelerate the trend. In plain terms, MACD below the signal line often means the rally is losing steam even if price is still holding above key moving averages.
